Patient, Physician And Nurse Factors Associated With Entry Onto Clinical Trials And Completion Of Treatment For Women With Primary Or Recurrent Invasive Cancer Of The Uterine Corpus Or Uterine Cervix, All Stages

Trial Information

Patient, Physician And Nurse Factors Associated With Entry Onto Clinical Trials And Completion Of Treatment For Women With Primary Or Recurrent Invasive Cancer Of The Uterine Corpus Or Uterine Cervix, All Stages

OBJECTIVES:

Primary

- To determine if there are specific, modifiable factors relative to patients,
physicians, nurses, or clinical trial designs that predict enrollment or non-enrollment
onto a GOG therapeutic trial for patients with primary or recurrent invasive cancer of
the uterine corpus or cervix.

- To determine if the Functional Comorbidity Index is an independent predictor of
enrollment in a GOG clinical trial and if it correlates with performance status.

Secondary

- To determine, through multivariate analyses, whether the distribution of patients into
a GOG clinical trial entry status categories (i.e., enrolled, not enrolled but
eligible, not eligible) varies by demographics or economic status of patients, by
patients' beliefs/concerns and interactions with physicians/family and friends, or by
nurses' or physicians' beliefs/concerns and interactions with patients.

- To determine whether patients' beliefs/concerns or interactions are associated with
patient, nurse, or physician demographics.

- To determine whether physicians' beliefs/concerns or interactions are associated with
patient or physician demographics.

- To perform descriptive analysis regarding factors associated with completion of
treatment through analysis of the Treatment Review Form.

OUTLINE: This is a multicenter study.

At baseline, patients' medical record information is collected; sites complete the
Functional Comorbidity Index; and physicians, nurses, and study coordinators complete the
follow-up questionnaire. Patients may also complete the Patient Registration Survey and
Patient Questionnaire at baseline. Staff complete the treatment review form after treatment
or 7 months after study registration.